Yu Wang1, Longfei Li2, Xiyao Liu3, Yihua Wang1, Zhenrong Tang1, Yinan Wu1, Yudi Jin1, Shengchun Liu1. 1. Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. School of Public Health and Management, Chongqing Medical University, Chongqing, China. 3. Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Abstract
BACKGROUND: Excellent response of the primary tumor after neoadjuvant therapy may indicate a better axillary status in breast cancer. However, this treatment response correlation has not been investigated in Chinese breast cancer patients. METHODS: Patients diagnosed with breast cancer and treated with neoadjuvant therapy were included in this retrospective study, conducted at a comprehensive breast cancer institution in China. Clinicopathological factors at baseline were analyzed by univariate and multivariate analyses. Furthermore, association rules analyses were used to investigate the correlation between the pathologic response of the primary tumor and that of the axillary lymph nodes based on such factors. RESULTS: Multivariate logistic regression analysis showed that breast pathologic response was influenced by tumor size, classification of regional lymph nodes, histological grade, progesterone receptor status, and Ki67 expression. The potential influencing factor for the pathologic response of the axilla was found to be regional lymph node classification. The findings from association rules analyses demonstrated that when a pathologic complete response (pCR) in the breast was achieved among patients with cT2N0 and hormone receptor-negative disease, the axilla response in these patients was also highly likely to be pCR (the likelihood for axilla pCR was more than 90%). However, cT3N1-2 patients hardly achieved pCR for both the primary tumor and axillary lymph nodes (mean confidence, 0.9637). The clinicopathological factors accounting for the inconsistent response between the breast and the axilla were found to be hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, and low Ki67 expression. CONCLUSIONS: Our findings suggest a strong correlation between breast pCR and axilla pCR among patients with specific characteristics. These findings provide a basis for the selection of candidates for clinical trials on the omission of axillary surgery. 2021 Gland Surgery. All rights reserved.
BACKGROUND: Excellent response of the primary tumor after neoadjuvant therapy may indicate a better axillary status in breast cancer. However, this treatment response correlation has not been investigated in Chinese breast cancer patients. METHODS: Patients diagnosed with breast cancer and treated with neoadjuvant therapy were included in this retrospective study, conducted at a comprehensive breast cancer institution in China. Clinicopathological factors at baseline were analyzed by univariate and multivariate analyses. Furthermore, association rules analyses were used to investigate the correlation between the pathologic response of the primary tumor and that of the axillary lymph nodes based on such factors. RESULTS: Multivariate logistic regression analysis showed that breast pathologic response was influenced by tumor size, classification of regional lymph nodes, histological grade, progesterone receptor status, and Ki67 expression. The potential influencing factor for the pathologic response of the axilla was found to be regional lymph node classification. The findings from association rules analyses demonstrated that when a pathologic complete response (pCR) in the breast was achieved among patients with cT2N0 and hormone receptor-negative disease, the axilla response in these patients was also highly likely to be pCR (the likelihood for axilla pCR was more than 90%). However, cT3N1-2 patients hardly achieved pCR for both the primary tumor and axillary lymph nodes (mean confidence, 0.9637). The clinicopathological factors accounting for the inconsistent response between the breast and the axilla were found to be hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, and low Ki67 expression. CONCLUSIONS: Our findings suggest a strong correlation between breast pCR and axilla pCR among patients with specific characteristics. These findings provide a basis for the selection of candidates for clinical trials on the omission of axillary surgery. 2021 Gland Surgery. All rights reserved.
Entities:
Keywords:
Breast cancer; axillary surgery; neoadjuvant therapy; quality of life (QOL)
Authors: Nehmat Houssami; Petra Macaskill; Gunter von Minckwitz; Michael L Marinovich; Eleftherios Mamounas Journal: Eur J Cancer Date: 2012-07-03 Impact factor: 9.162
Authors: M Kaufmann; G von Minckwitz; H D Bear; A Buzdar; P McGale; H Bonnefoi; M Colleoni; C Denkert; W Eiermann; R Jackesz; A Makris; W Miller; J-Y Pierga; V Semiglazov; A Schneeweiss; R Souchon; V Stearns; M Untch; S Loibl Journal: Ann Oncol Date: 2007-11-12 Impact factor: 32.976
Authors: Anita Mamtani; Andrea V Barrio; Tari A King; Kimberly J Van Zee; George Plitas; Melissa Pilewskie; Mahmoud El-Tamer; Mary L Gemignani; Alexandra S Heerdt; Lisa M Sclafani; Virgilio Sacchini; Hiram S Cody; Sujata Patil; Monica Morrow Journal: Ann Surg Oncol Date: 2016-05-09 Impact factor: 5.344
Authors: Alison U Barron; Tanya L Hoskin; Courtney N Day; E Shelley Hwang; Henry M Kuerer; Judy C Boughey Journal: JAMA Surg Date: 2018-12-01 Impact factor: 14.766
Authors: Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Winkle Kwan; Jeremy Jackson; Lorna M Weir; Carol Dingee; Greg McGregor; Ivo A Olivotto Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: Caridad Díaz; Carmen González-Olmedo; Leticia Díaz-Beltrán; José Camacho; Patricia Mena García; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Juan Antonio Marchal; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira Journal: Mol Oncol Date: 2022-04-14 Impact factor: 7.449